Elevated p-eIF2α has also been observed in different gastrointestinal malignancies as well as other tumor entities including pancreatic cancer, breast cancer, prostate cancer and MYC-driven lymphoma where it is partially involved in tumor progression (Bai et al, 2021; Guo et al, 2017; Hart et al, 2012; Koromilas, 2015; Lobo et al, 2000; Nguyen et al, 2018; Shin et al, 2022). This evidence concerns the gene MYC and prostate carcinoma.